BioScrip Reports Second Quarter 2018 Financial Results
August 07 2018 - 8:00AM
BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the
largest independent national provider of infusion and home care
management solutions, today announced its second quarter 2018
financial results.
Second Quarter 2018
Highlights
- Net revenue of $175.8 million, including core product mix of
75.1%, compared to 73.6% in the prior year quarter, reflecting the
impact of the implementation of ASC 606*, which resulted in the
recognition of amounts previously reported as bad debt expense as a
reduction to revenue
- Net loss from continuing operations of $15.1 million, a $14.0
million improvement compared to the prior year quarter
- Adjusted EBITDA of $11.4 million, 14% above the prior year
quarter, driven by a 510 basis point improvement in gross profit
margin and a $3.0 million reduction in operating expenses,
reflecting ASC 606 pro forma adjustments
- Net cash used in operating activities of $15.1 million,
reflecting operational cash use of $7.8 million and interest
payments of $7.3 million
- Liquidity of $20.8 million at June 30, 2018, consisting of cash
and equivalents
- Operational cash flow and liquidity impacted by the timing of
strategic inventory purchases related to product shortages and
recalls, temporary decreases in cash collections of accounts
receivable, as well as payment of 2017 incentive compensation;
operational cash flow is expected to return to more normalized
levels beginning in the third quarter of 2018
Daniel E. Greenleaf, President and Chief
Executive Officer, commented, “BioScrip achieved record second
quarter adjusted EBITDA of $11.4 million, up 14% compared to the
prior year period, driven by improved core product mix, higher
gross profit margin, and ongoing operating expense discipline. We
commenced the third quarter with our best sales month of the year
during July and are reaffirming our full year 2018 guidance for
revenue between $688 million and $698 million*, and adjusted EBITDA
between $54 million and $58 million.
“We remain increasingly confident that BioScrip
can achieve at least $75 million in adjusted EBITDA in 2019 and are
positioning the Company for revitalized longer-term revenue growth
and enhanced profitability though key initiatives in sales force
productivity, revenue cycle management, procurement and managed
care relationships.”
* Implementation of ASC 606 during the first
quarter of 2018 resulted in the recognition of amounts previously
recorded as bad debt expense as a reduction to revenue. The impact
of the change in accounting principle reduced both revenue and bad
debt expense by $5.4 million during the second quarter. The
implementation of ASC 606 did not impact operating income or
Adjusted EBITDA during the second quarter of 2018 and will not
impact operating income or Adjusted EBITDA on a go-forward basis.
The implementation of ASC 606 in the first quarter of 2018 resulted
in a reduction of our 2018 revenue guidance by approximately $22
million but did not impact 2018 Adjusted EBITDA guidance.
Conference Call and
Presentation
BioScrip will host a conference call and live
webcast on August 7, 2018, at 9:00 a.m. Eastern Time, to discuss
its second quarter 2018 financial results. Interested parties may
participate by dialing 877-423-9820 (U.S.) or by accessing a link
under the "Investors" section on the Company's website at
www.bioscrip.com.
An audio webcast and archive will be available
within two hours of the call’s completion under the “Investors"
section of the Company's website.
About BioScrip, Inc.
BioScrip, Inc. is the largest independent
national provider of infusion and home care management solutions,
with approximately 2,100 teammates and nearly 70 service locations
across the U.S. BioScrip partners with physicians, hospital
systems, payors, pharmaceutical manufacturers and skilled nursing
facilities to provide patients access to post-acute care services.
BioScrip operates with a commitment to bring customer-focused
pharmacy and related healthcare infusion therapy services into the
home or alternate-site setting. By collaborating with the full
spectrum of healthcare professionals and the patient, BioScrip
provides cost-effective care that is driven by clinical excellence,
customer service, and values that promote positive outcomes and an
enhanced quality of life for those it serves.
Investor Contacts
Stephen Deitsch
Kalle Ahl, CFAChief Financial Officer &
Treasurer
The Equity GroupT: (720) 697-5200
T: (212) 836-9614stephen.deitsch@bioscrip.com
kahl@equityny.com
Forward-Looking Statements – Safe
Harbor
This press release includes statements that may
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including the
statements regarding guidance, projections of certain measures of
the Company's results of operations, projections of future levels
of certain charges and expenses, incremental cost structure
improvements and other statements regarding the Company's financial
improvement plan and strategy and anticipated effects of the Cures
Act. You can identify these statements by the fact that they do not
relate strictly to historical or current facts. In some cases,
forward-looking statements can be identified by words such as
"may," "should," "could," "anticipate," "estimate," "expect,"
"project," "outlook," "aim," "intend," "plan," "believe,"
"predict," "potential," "continue" or comparable terms. Because
such statements inherently involve risks and uncertainties, actual
future results may differ materially from those expressed or
implied by such forward-looking statements. Investors are cautioned
that any such forward-looking statements are not guarantees of
future performance and involve risks and uncertainties, and that
actual results may differ materially from those in the
forward-looking statements as a result of various factors.
Important factors that could cause actual results to differ
materially from those in the forward-looking statement include but
are not limited to risks associated with: the Company’s ability to
make principal and interest payments on our debt and unsecured
notes and satisfy the other covenants contained in its debt
agreements; the Company’s ability to grow its core Infusion
revenues; the Company's ability to continue to execute its
financial improvement plan to reduce operating costs and focus its
business on its Infusion Services segment; the Company’s ability to
evaluate opportunities for improvement and implement solutions as
part of its strategic review process; the success of the Company’s
initiatives to mitigate the impact of the Cures Act on its
business; reductions in federal, state and commercial reimbursement
for the Company's products and services; increased government
regulation related to the health care and insurance industries; as
well as the risks described in the Company's periodic filings with
the Securities and Exchange Commission. The Company does not
undertake any duty to update these forward-looking statements after
the date hereof, even though the Company's situation may change in
the future. All of the forward-looking statements herein are
qualified by these cautionary statements.
Note Regarding Use of Non-GAAP Financial
Measures
In addition to reporting financial information
in accordance with generally accepted accounting principles (GAAP),
the Company is also reporting Adjusted EBITDA, which is a non-GAAP
financial measure. Adjusted EBITDA is not a measurement of
financial performance under GAAP and should not be used in
isolation or as a substitute or alternative to net income,
operating income or any other performance measure derived in
accordance with GAAP, or as a substitute or alternative to cash
flow from operating activities or a measure of the Company’s
liquidity. In addition, the Company's definition of Adjusted EBITDA
may not be comparable to similarly titled non-GAAP financial
measures reported by other companies. Adjusted EBITDA, as defined
by the Company, represents net income before net interest expense,
income tax expense, depreciation and amortization, impairment of
goodwill, stock-based compensation expense, and restructuring,
integration and other expenses. As part of restructuring, the
Company may incur significant charges such as the write down of
certain long−lived assets, temporary redundant expenses, retraining
expenses, potential cash bonus payments and potential accelerated
payments or terminated costs for certain of its contractual
obligations. Management believes that Adjusted EBITDA provides
useful supplemental information regarding the performance of
BioScrip’s business operations and facilitates comparisons to the
Company’s historical operating results. For a full reconciliation
of Adjusted EBITDA to the most comparable GAAP financial measure,
please see the attachment to this earnings release.
|
Schedule 1 |
BIOSCRIP, INC. AND SUBSIDIARIES |
CONSOLIDATED BALANCE SHEETS |
(in thousands, except for share amounts) |
(unaudited) |
|
|
|
|
|
June 30, 2018 |
|
December 31, 2017 |
|
|
|
|
ASSETS |
|
|
|
Current
assets |
|
|
|
Cash and
cash equivalents |
$ |
20,820 |
|
|
$ |
39,457 |
|
Restricted cash |
|
4,950 |
|
|
|
4,950 |
|
Receivables, less allowance for doubtful accounts of $0 and $37,912
as of June 30, 2018 |
|
|
|
and
December 31, 2017, respectively |
|
96,917 |
|
|
|
85,522 |
|
Inventory |
|
25,286 |
|
|
|
38,044 |
|
Prepaid
expenses and other current assets |
|
8,583 |
|
|
|
18,620 |
|
Total current assets |
|
156,556 |
|
|
|
186,593 |
|
Property and equipment,
net of accumulated depreciation of $92,588 and $86,675 as of |
|
|
|
June 30,
2018 and December 31, 2017, respectively |
|
25,004 |
|
|
|
26,973 |
|
Goodwill |
|
367,198 |
|
|
|
367,198 |
|
Intangible assets, net
of accumulated amortization of $44,904 and $40,036 as of June 30,
2018 |
|
|
|
and
December 31, 2017, respectively |
|
14,247 |
|
|
|
19,114 |
|
Deferred income
taxes |
|
1,041 |
|
|
|
1,098 |
|
Other non-current
assets |
|
2,100 |
|
|
|
2,116 |
|
Total assets |
$ |
566,146 |
|
|
$ |
603,092 |
|
LIABILITIES AND
STOCKHOLDERS' DEFICIT |
|
|
|
Current
liabilities |
|
|
|
Current
portion of long-term debt |
$ |
957 |
|
|
$ |
1,722 |
|
Accounts
payable |
|
49,264 |
|
|
|
65,963 |
|
Amounts
due to plan sponsors |
|
2,184 |
|
|
|
4,621 |
|
Accrued
interest |
|
6,728 |
|
|
|
6,706 |
|
Accrued
expenses and other current liabilities |
|
23,028 |
|
|
|
26,118 |
|
Total current liabilities |
|
82,161 |
|
|
|
105,130 |
|
Long-term debt, net of
current portion |
|
492,309 |
|
|
|
478,866 |
|
Other non-current
liabilities |
|
21,151 |
|
|
|
21,769 |
|
Total liabilities |
|
595,621 |
|
|
|
605,765 |
|
Series A
convertible preferred stock, $.0001 par value; 825,000 shares
authorized; |
|
|
|
21,643
shares issued and outstanding as of June 30, 2018 and December 31,
2017; |
|
|
|
and
$3,084 and $2,916 liquidation preference as of June 30, 2018 and
December 31, 2017, |
|
|
|
respectively |
|
3,022 |
|
|
|
2,827 |
|
Series C
convertible preferred stock, $.0001 par value; 625,000 shares
authorized; |
|
|
|
614,177
shares issued and outstanding as of June 30, 2018 and December 31,
2017; |
|
|
|
and
$89,455 and $84,555 liquidation preference as of June 30, 2018 and
December 31, 2017, |
|
|
|
respectively |
|
84,469 |
|
|
|
79,252 |
|
Stockholders'
deficit |
|
|
|
Preferred stock, $.0001 par value; 5,000,000 shares
authorized; no shares issued and |
|
|
|
outstanding as of June 30, 2018 and December 31, 2017,
respectively |
|
- |
|
|
|
- |
|
Common stock, $.0001 par value; 250,000,000 shares authorized;
128,046,122 and 127,634,012 |
|
|
shares
issued and outstanding as of June 30, 2018 and December 31, 2017,
respectively |
|
13 |
|
|
|
13 |
|
Treasury
stock, 110,496 and 5,106 shares outstanding, at cost, as of June
30, 2018 and |
|
|
|
December
31, 2017, respectively |
|
(327 |
) |
|
|
(16 |
) |
Additional paid-in capital |
|
621,015 |
|
|
|
624,762 |
|
Accumulated deficit |
|
(737,667 |
) |
|
|
(709,511 |
) |
Total stockholders' deficit |
|
(116,966 |
) |
|
|
(84,752 |
) |
Total liabilities and stockholders' deficit |
$ |
566,146 |
|
|
$ |
603,092 |
|
|
|
|
|
|
Schedule 2 |
BIOSCRIP, INC. AND SUBSIDIARIES |
CONSOLIDATED STATEMENTS OF
OPERATIONS |
(in thousands, except per share amounts) |
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June
30, |
|
|
|
2018 |
|
2017 |
|
2018 |
|
2017 |
|
|
|
|
|
|
|
|
|
|
Net
revenue |
|
|
$ |
175,789 |
|
|
$ |
218,106 |
|
|
$ |
344,373 |
|
|
$ |
435,916 |
|
Cost of revenue
(excluding depreciation expense) |
|
|
|
115,832 |
|
|
|
150,495 |
|
|
|
229,368 |
|
|
|
303,430 |
|
Gross
profit |
|
|
|
59,957 |
|
|
|
67,611 |
|
|
|
115,005 |
|
|
|
132,486 |
|
% of
revenues |
|
|
|
34.1 |
% |
|
|
31.0 |
% |
|
|
33.4 |
% |
|
|
30.4 |
% |
|
|
|
|
|
|
|
|
|
|
Other operating
expenses |
|
|
|
38,861 |
|
|
|
42,293 |
|
|
|
78,160 |
|
|
|
86,612 |
|
Bad debt expense |
|
|
|
- |
|
|
|
6,117 |
|
|
|
- |
|
|
|
13,160 |
|
General and
administrative expenses |
|
|
|
10,931 |
|
|
|
9,654 |
|
|
|
21,600 |
|
|
|
18,920 |
|
Restructuring,
acquisition, integration, and other expenses, net |
|
|
|
2,024 |
|
|
|
4,147 |
|
|
|
3,906 |
|
|
|
7,370 |
|
Change in fair value of
equity linked liabilities |
|
|
|
3,064 |
|
|
|
- |
|
|
|
(375 |
) |
|
|
- |
|
Depreciation and
amortization expense |
|
|
|
6,366 |
|
|
|
7,065 |
|
|
|
12,852 |
|
|
|
14,230 |
|
Interest expense |
|
|
|
13,805 |
|
|
|
12,630 |
|
|
|
27,200 |
|
|
|
25,290 |
|
Loss on extinguishment
of debt |
|
|
|
- |
|
|
|
13,453 |
|
|
|
- |
|
|
|
13,453 |
|
(Gain) loss on
dispositions |
|
|
|
(13 |
) |
|
|
685 |
|
|
|
(318 |
) |
|
|
685 |
|
Loss from continuing operations, before income
taxes |
|
|
|
(15,081 |
) |
|
|
(28,433 |
) |
|
|
(28,020 |
) |
|
|
(47,234 |
) |
Income tax expense |
|
|
|
43 |
|
|
|
718 |
|
|
|
91 |
|
|
|
1,337 |
|
Loss from continuing operations, net of income
taxes |
|
|
|
(15,124 |
) |
|
|
(29,151 |
) |
|
|
(28,111 |
) |
|
|
(48,571 |
) |
Loss from discontinued
operations, net of income taxes |
|
|
|
(15 |
) |
|
|
(373 |
) |
|
|
(45 |
) |
|
|
(672 |
) |
Net loss |
|
|
$ |
(15,139 |
) |
|
$ |
(29,524 |
) |
|
$ |
(28,156 |
) |
|
$ |
(49,243 |
) |
Dividends on preferred
stock |
|
|
|
(2,756 |
) |
|
|
(2,478 |
) |
|
|
(5,413 |
) |
|
|
(4,866 |
) |
Loss attributable to common stockholders |
|
|
$ |
(17,895 |
) |
|
$ |
(32,002 |
) |
|
$ |
(33,569 |
) |
|
$ |
(54,109 |
) |
|
|
|
|
|
|
|
|
|
|
Loss per common
share: |
|
|
|
|
|
|
|
|
|
Loss from continuing
operations, basic and diluted |
|
|
$ |
(0.14 |
) |
|
$ |
(0.26 |
) |
|
$ |
(0.26 |
) |
|
$ |
(0.44 |
) |
Loss from discontinued
operations, basic and diluted |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(0.01 |
) |
Loss per common
share, basic and diluted |
|
|
$ |
(0.14 |
) |
|
$ |
(0.26 |
) |
|
$ |
(0.26 |
) |
|
$ |
(0.45 |
) |
|
|
|
|
|
|
|
|
|
|
Weighted
average number of common shares outstanding, |
|
|
|
|
|
|
|
|
|
basic and
diluted |
|
|
|
128,038 |
|
|
|
121,189 |
|
|
|
127,906 |
|
|
|
119,993 |
|
|
|
|
|
|
|
|
|
|
|
|
Schedule 3 |
BIOSCRIP, INC. AND SUBSIDIARIES |
QUARTERLY
RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES |
(in thousands) |
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
Six Months Ended June
30, |
|
|
2018 |
|
2017 |
|
2018 |
|
2017 |
|
|
|
|
|
|
|
|
|
Loss from
continuing operations, net of income taxes |
|
|
(15,124 |
) |
|
|
(29,151 |
) |
|
|
(28,111 |
) |
|
|
(48,571 |
) |
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(13,805 |
) |
|
|
(12,630 |
) |
|
|
(27,200 |
) |
|
|
(25,290 |
) |
Change in fair value of
equity linked liabilities |
|
|
(3,064 |
) |
|
|
- |
|
|
|
375 |
|
|
|
- |
|
Gain (loss) on
dispositions |
|
|
13 |
|
|
|
(685 |
) |
|
|
318 |
|
|
|
(685 |
) |
Loss on extinguishment
of debt |
|
|
- |
|
|
|
(13,453 |
) |
|
|
- |
|
|
|
(13,453 |
) |
Income tax expense |
|
|
(43 |
) |
|
|
(718 |
) |
|
|
(91 |
) |
|
|
(1,337 |
) |
Depreciation and
amortization expense |
|
|
(6,366 |
) |
|
|
(7,065 |
) |
|
|
(12,852 |
) |
|
|
(14,230 |
) |
Stock-based
compensation expense |
|
|
(1,253 |
) |
|
|
(433 |
) |
|
|
(1,808 |
) |
|
|
(1,027 |
) |
Restructuring,
acquisition, integration, and other expenses, net (1) |
|
|
(2,024 |
) |
|
|
(4,147 |
) |
|
|
(3,906 |
) |
|
|
(7,370 |
) |
Consolidated
Adjusted EBITDA |
|
$ |
11,418 |
|
|
$ |
9,980 |
|
|
$ |
17,053 |
|
|
$ |
14,821 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Restructuring, acquisition, integration and other
expenses, net include costs associated with restructuring,
acquisition, and integration initiatives such as employee severance
costs, certain legal and professional fees, redundant wage costs,
impacts recorded from the change in contingent consideration
obligations, and other costs related to contract terminations and
closed locations. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Schedule 4 |
BIOSCRIP, INC AND SUBSIDIARIES |
CONSOLIDATED CONDENSED CASH
FLOWS |
(in thousands) |
(unaudited) |
|
|
|
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
March 31, 2018 |
|
June 30, 2018 |
|
|
June 30, 2018 |
Cash flows from
operating activities: |
|
|
|
|
|
|
Net loss |
$ |
(13,017 |
) |
|
$ |
(15,139 |
) |
|
|
$ |
(28,156 |
) |
Less: Loss from
discontinued operations, net of income taxes |
|
(30 |
) |
|
|
(15 |
) |
|
|
|
(45 |
) |
Loss from continuing
operations, net of income taxes |
|
(12,987 |
) |
|
|
(15,124 |
) |
|
|
|
(28,111 |
) |
Adjustments to
reconcile net loss from continuing operations, net of income taxes
to net cash used in operating activities: |
|
|
|
|
|
|
Depreciation and amortization |
|
6,486 |
|
|
|
6,366 |
|
|
|
|
12,852 |
|
Amortization of deferred financing costs and debt discount |
|
2,023 |
|
|
|
2,048 |
|
|
|
|
4,071 |
|
Change in
fair value of equity linked liabilities |
|
(3,439 |
) |
|
|
3,064 |
|
|
|
|
(375 |
) |
Change in
deferred income taxes |
|
31 |
|
|
|
25 |
|
|
|
|
56 |
|
Stock-based compensation |
|
556 |
|
|
|
1,253 |
|
|
|
|
1,809 |
|
Gain on
dispositions |
|
(305 |
) |
|
|
(13 |
) |
|
|
|
(318 |
) |
Changes
in assets and liabilities: |
|
|
|
|
|
|
Receivables |
|
(2,663 |
) |
|
|
(8,734 |
) |
|
|
|
(11,397 |
) |
Inventory |
|
(3,505 |
) |
|
|
16,264 |
|
|
|
|
12,759 |
|
Prepaid
expenses and other assets |
|
8,807 |
|
|
|
1,247 |
|
|
|
|
10,054 |
|
Accounts
payable |
|
2,872 |
|
|
|
(19,574 |
) |
|
|
|
(16,702 |
) |
Amounts
due to plan sponsors |
|
(969 |
) |
|
|
(1,468 |
) |
|
|
|
(2,437 |
) |
Accrued
interest |
|
(4,487 |
) |
|
|
4,510 |
|
|
|
|
23 |
|
Accrued
expenses and other liabilities |
|
2,418 |
|
|
|
(4,984 |
) |
|
|
|
(2,566 |
) |
Net cash
used in operating activities from continuing operations |
|
(5,162 |
) |
|
|
(15,120 |
) |
|
|
|
(20,282 |
) |
Net cash
used in operating activities from discontinued operations |
|
(30 |
) |
|
|
(15 |
) |
|
|
|
(45 |
) |
Net cash used in operating activities |
|
(5,192 |
) |
|
|
(15,135 |
) |
|
|
|
(20,327 |
) |
Cash flows from
investing activities: |
|
|
|
|
|
|
Purchases
of property and equipment |
|
(2,646 |
) |
|
|
(4,300 |
) |
|
|
|
(6,946 |
) |
Net cash used in investing activities |
|
(2,646 |
) |
|
|
(4,300 |
) |
|
|
|
(6,946 |
) |
Cash flows from
financing activities: |
|
|
|
|
|
|
Borrowing
of long-term debt |
|
- |
|
|
|
10,000 |
|
|
|
|
10,000 |
|
Repayments of capital leases |
|
(967 |
) |
|
|
(218 |
) |
|
|
|
(1,185 |
) |
Net
activity from exercises of employee stock awards |
|
(300 |
) |
|
|
121 |
|
|
|
|
(179 |
) |
Net cash (used in) provided by financing
activities |
|
(1,267 |
) |
|
|
9,903 |
|
|
|
|
8,636 |
|
Net change in cash and
cash equivalents |
|
(9,105 |
) |
|
|
(9,532 |
) |
|
|
|
(18,637 |
) |
Cash and cash
equivalents - beginning of period |
|
44,407 |
|
|
|
35,302 |
|
|
|
|
44,407 |
|
Cash and cash
equivalents - end of period |
$ |
35,302 |
|
|
$ |
25,770 |
|
|
|
$ |
25,770 |
|
|
|
|
|
|
|
|
|
Schedule
5 |
|
|
|
|
BIOSCRIP, INC AND SUBSIDIARIES |
FULL YEAR 2018
GUIDANCE |
(dollars in millions, except EPS) |
(unaudited) |
|
Low
End |
|
High
End |
|
of
Range |
|
of
Range |
|
|
|
|
Revenues |
$ |
688.0 |
|
|
$ |
698.0 |
|
|
|
|
|
Loss from
continuing operations, net of income taxes |
|
(51.2 |
) |
|
|
(43.2 |
) |
|
|
|
|
Stock Compensation |
|
4.0 |
|
|
|
3.5 |
|
Depreciation &
Amortization |
|
27.0 |
|
|
|
26.0 |
|
Interest Expense,
net |
|
56.0 |
|
|
|
55.0 |
|
Restructuring
Costs |
|
6.0 |
|
|
|
5.0 |
|
Income Tax Expense |
|
1.0 |
|
|
|
0.5 |
|
Preferred Stock
Dividends |
|
11.2 |
|
|
|
11.2 |
|
Adjusted
EBITDA |
$ |
54.0 |
|
|
$ |
58.0 |
|
Adjusted EBITDA Margin |
|
7.8 |
% |
|
|
8.3 |
% |
|
|
|
|
Diluted Loss Per Common
Share |
$ |
(0.40 |
) |
|
$ |
(0.34 |
) |
|
|
|
|
Weighted-Average
Diluted Shares |
|
128.0 |
|
|
|
128.0 |
|
|
|
|
|
|
|
|
|
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Sep 2023 to Sep 2024